Breaking News, Collaborations & Alliances

AnaptysBio, Celgene In Strategic Antibody Pact

Aims to develop oncology and inflammation therapies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AnaptysBio has entered a strategic partnership with Celgene Corp. to develop novel antibodies against multiple therapeutic targets. AnaptysBio is responsible for generating novel therapeutic antibodies to oncology and inflammation-related targets using its SHM-XEL platform. Celgene will have worldwide rights to develop and commercialize any antibodies discovered under the terms of the partnership. AnaptysBio will receive an upfront payment, preclinical and clinical milestone payments, as well as...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters